Furthermore, pharmacological inhibition of the POSTN/TGFβ1/AP-2α axis with cilengitide, an αvβ3 integrin antagonist, combined with lenvatinib, an HCC first-line therapy, significantly enhanced therapeutic efficacy in preclinical models40. Here, TGFB1 is linked to hepatocellular carcinoma.